PT2885266T - Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo - Google Patents

Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo

Info

Publication number
PT2885266T
PT2885266T PT137793782T PT13779378T PT2885266T PT 2885266 T PT2885266 T PT 2885266T PT 137793782 T PT137793782 T PT 137793782T PT 13779378 T PT13779378 T PT 13779378T PT 2885266 T PT2885266 T PT 2885266T
Authority
PT
Portugal
Prior art keywords
propylimino
dihydroxypropoxy
thiazolidin
benzylidene
tolyl
Prior art date
Application number
PT137793782T
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of PT2885266T publication Critical patent/PT2885266T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/64Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/77Preparation of chelates of aldehydes or ketones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78Separation; Purification; Stabilisation; Use of additives
    • C07C45/81Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00Compounds having —CHO groups
    • C07C47/52Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54Nitrogen and either oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
PT137793782T 2012-08-17 2013-08-15 Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo PT2885266T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12180920 2012-08-17

Publications (1)

Publication Number Publication Date
PT2885266T true PT2885266T (pt) 2020-05-29

Family

ID=46940231

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137793782T PT2885266T (pt) 2012-08-17 2013-08-15 Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo

Country Status (20)

Country Link
US (1) US9340518B2 (pt)
EP (1) EP2885266B1 (pt)
JP (2) JP6322630B2 (pt)
KR (1) KR101731739B1 (pt)
CN (1) CN104540800B (pt)
CA (1) CA2895172C (pt)
CY (1) CY1123300T1 (pt)
DK (1) DK2885266T3 (pt)
ES (1) ES2795105T3 (pt)
HR (1) HRP20200883T1 (pt)
HU (1) HUE050733T2 (pt)
IL (1) IL237198A (pt)
LT (1) LT2885266T (pt)
MX (1) MX350891B (pt)
PL (1) PL2885266T3 (pt)
PT (1) PT2885266T (pt)
RS (1) RS60408B1 (pt)
SI (1) SI2885266T1 (pt)
TW (1) TWI606036B (pt)
WO (1) WO2014027330A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009115954A1 (en) 2008-03-17 2009-09-24 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
PT2885266T (pt) * 2012-08-17 2020-05-29 Actelion Pharmaceuticals Ltd Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
AU2015359346B2 (en) 2014-12-11 2020-05-07 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
US10487064B1 (en) 2015-12-25 2019-11-26 Crystal Pharmatech Co., Ltd. Crystalline forms of selective S1P1 receptor modulator and preparation method thereof
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
WO2019060147A1 (en) * 2017-09-19 2019-03-28 Teva Pharmaceuticals Usa, Inc. NEW CRYSTALLINE POLYMORPHE FROM PONESIMOD
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
KR102365655B1 (ko) 2018-11-29 2022-02-22 원광대학교 산학협력단 콩 발효 추출물을 유효성분으로 포함하는 피부 주름 예방 또는 개선용 조성물
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2023022896A1 (en) 2021-08-17 2023-02-23 Teva Czech Industries S.R.O Polymorphs of ponesimod
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2023152691A1 (en) * 2022-02-10 2023-08-17 Metrochem Api Pvt Ltd Process for the preparation of ponesimod and its intermediates thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3077402A (en) 1954-12-06 1963-02-12 Polaroid Corp Photographic color processes, products, and compositions
NL270002A (pt) 1960-10-08
GB1001479A (en) 1962-10-10 1965-08-18 Angeli Inst Spa Glycerol ethers
OA03835A (fr) 1970-07-17 1971-12-24 Rhone Poulenc Sa Nouveaux dérivés de la thiazolidine, leur préparation et les compositions qui les contiennent.
HU214872B (hu) 1990-04-27 1998-07-28 Orion-Yhtymä Oy Eljárás farmakológiailag aktív új katecholszármazékok és ezeket tartalmazó gyógyászati készítmények előállítására
TW221689B (pt) 1991-08-27 1994-03-11 Otsuka Pharma Co Ltd
CA2134347C (en) 1993-02-26 2003-04-29 Koichi Yasumura Thiazole or imidazole derivatives as maillard reaction inhibitors
KR960022486A (ko) 1994-12-29 1996-07-18 김준웅 신규 티아졸리딘-4-온 유도체
US6353006B1 (en) 1999-01-14 2002-03-05 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
AU6877300A (en) 1999-09-14 2001-04-17 Shionogi & Co., Ltd. 2-imino-1,3-thiazine derivatives
DE69934027T2 (de) 1999-11-12 2007-06-21 Fujimoto Brothers Co., Ltd., Matubara 2-(n-cyanimino)thiazolidin-4-on derivate
US20050019825A9 (en) 2002-03-15 2005-01-27 Qing Dong Common ligand mimics: pseudothiohydantoins
AU2003255528B2 (en) 2002-07-10 2009-07-16 Merck Serono Sa Azolidinone-vinyl fused-benzene derivatives
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds
WO2004014313A2 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
KR20050085115A (ko) 2002-11-22 2005-08-29 스미스클라인 비참 코포레이션 신규 화합물
US20040167192A1 (en) 2003-01-16 2004-08-26 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
US7892354B2 (en) 2003-10-06 2011-02-22 Solvias Ag Process for the parallel detection of crystalline forms of molecular solids
DE602004029493D1 (de) 2003-11-21 2010-11-18 Actelion Pharmaceuticals Ltd 5-(benz- (z) -yliden) -thiazolidin-4-onderivate als das immunsystem unterdrückende mittel
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
JP2007523957A (ja) 2004-02-25 2007-08-23 スミスクライン・ビーチャム・コーポレイション 新規化学化合物
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
JP2008521827A (ja) 2004-11-29 2008-06-26 ノバルティス アクチエンゲゼルシャフト S1p受容体アゴニストの投与レジメン
WO2006094233A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N,n'-dicyclic isothiourea sirtuin modulators
JP5047941B2 (ja) 2005-03-23 2012-10-10 アクテリオン ファーマシューティカルズ リミテッド 免疫調節物質としての水素付加されたベンゾ(c)チオフェン誘導体
RU2404178C2 (ru) 2005-03-23 2010-11-20 Актелион Фармасьютиклз Лтд Новые производные тиофена в качестве агонистов рецептора сфингозин-1-фосфата-1
CN101180050B (zh) 2005-03-23 2011-07-27 埃科特莱茵药品有限公司 作为鞘氨醇-1-磷酸盐-1受体激动剂的新颖噻吩衍生物
AU2006260573A1 (en) 2005-06-24 2006-12-28 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
TWI404706B (zh) 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
EP1979345B1 (en) 2006-01-24 2009-11-04 Actelion Pharmaceuticals Ltd. Novel pyridine derivatives
US7879821B2 (en) 2006-01-26 2011-02-01 University Of Medicine And Dentistry Of New Jersey Method for modulating inflammatory responses by altering plasma lipid levels
AU2007292993B2 (en) 2006-09-07 2013-01-24 Idorsia Pharmaceuticals Ltd Pyridin-4-yl derivatives as immunomodulating agents
AR061841A1 (es) 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
CA2661315C (en) 2006-09-08 2015-11-24 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents
RU2442780C2 (ru) 2006-09-21 2012-02-20 Актелион Фармасьютиклз Лтд Фенильные производные и их применение в качестве иммуномодуляторов
DK2094676T3 (da) 2006-11-23 2013-06-10 Actelion Pharmaceuticals Ltd Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
DK2125797T3 (da) 2007-03-16 2014-02-10 Actelion Pharmaceuticals Ltd Aminopyridinderivater som s1p1/edg1-receptoragonister
SI2195311T1 (sl) 2007-08-17 2011-07-29 Actelion Pharmaceuticals Ltd Derivati piridina kot modulatorji receptorja s1p1/edg1
WO2009115954A1 (en) 2008-03-17 2009-09-24 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
GB0819182D0 (en) * 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
US20100160369A1 (en) 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using
PL2379069T3 (pl) 2008-12-22 2015-08-31 Novartis Ag Schemat dawkowania agonisty receptora S1P
SI3409274T1 (sl) 2008-12-22 2020-03-31 Novartis Ag Režim odmerjanja za S1P receptor agonist
PT2885266T (pt) * 2012-08-17 2020-05-29 Actelion Pharmaceuticals Ltd Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo

Also Published As

Publication number Publication date
TWI606036B (zh) 2017-11-21
HUE050733T2 (hu) 2021-01-28
IL237198A0 (en) 2015-04-30
CY1123300T1 (el) 2021-12-31
JP2017160223A (ja) 2017-09-14
KR101731739B1 (ko) 2017-05-11
KR20150042277A (ko) 2015-04-20
US9340518B2 (en) 2016-05-17
PL2885266T3 (pl) 2020-11-16
JP6424250B2 (ja) 2018-11-14
EP2885266A1 (en) 2015-06-24
MX2015002127A (es) 2015-05-11
US20150203459A1 (en) 2015-07-23
DK2885266T3 (da) 2020-06-08
SI2885266T1 (sl) 2020-10-30
CA2895172C (en) 2020-08-18
CA2895172A1 (en) 2014-02-20
CN104540800B (zh) 2017-05-10
EP2885266B1 (en) 2020-03-18
CN104540800A (zh) 2015-04-22
LT2885266T (lt) 2020-07-10
RS60408B1 (sr) 2020-07-31
WO2014027330A1 (en) 2014-02-20
JP6322630B2 (ja) 2018-05-09
IL237198A (en) 2017-12-31
TW201408634A (zh) 2014-03-01
ES2795105T3 (es) 2020-11-20
HRP20200883T1 (hr) 2020-09-04
MX350891B (es) 2017-09-22
JP2015530373A (ja) 2015-10-15

Similar Documents

Publication Publication Date Title
PT2885266T (pt) Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo
BR112015002541A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BR112014010179A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
HK1199712A1 (en) 18-methyl-6,7-methylene-3-oxo-17-pregn-4-ene-21,17-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis 18--67--3--17--4--2117-
EP2851429A4 (en) PROTEIN AND PROTEIN CONJUGATES FOR THE TREATMENT OF DIABETES AND APPLICATIONS THEREOF
HK1216146A1 (zh) 眼藥組合物、其製備方法及用途
BR112015031979A2 (pt) letermovir, formulação farmacêutica oral sólida, uso de uma formulação farmacêutica oral sólida, e processo para preparar letermovir.
IL239940B (en) History of 2-[3-(diazolyl)phenyl]-3,1-thiazole-5-carboxylic acid and intermediates obtained in the process for their preparation
EP3403675A4 (en) VIRION ADENO-ASSOCIATED VIRAL FOR ITS USE IN THE TREATMENT OF EPILEPSY
BR112013022523A2 (pt) uso de glicopirrolato para o tratamento de taquicardia
HRP20181282T1 (hr) Farmaceutski pripravak ibuprofena i tramadola, namijenjen očnoj upotrebi
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
BR112015012443A2 (pt) composição de limpeza, método de limpeza do corpo humano, uso da composição e método para prover limpeza
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
BR112013006857A2 (pt) composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica e método para o tratamento ou profilaxia de doenças virais
BR112014030949A2 (pt) "composição, processo para o tratamento cosmético e uso de uma composição"
EP3476864A4 (en) ANTIBODIES AGAINST ETAR, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP3328388A4 (en) PHARMACEUTICAL PREPARATION FOR IMPROVING THE INPUT AND POSTPRANDIAL HYPOGLYKEMIC EFFECT OF INSULIN
EP3175851A4 (en) Use of butenylphthalide, usage method thereof and method for preparing same into pharmaceutical composition
BR112015001169A2 (pt) polimorfo, uso do polimorfo, composição farmacêutica e uso para preparar o polimorfo